ストックスクリーナーアプリを入手
0.4153
6.54%
-0.0267
前日終値:
$0.442
開ける：
$0.45
24時間の取引高:
121.34K
Relative Volume:
0.10
時価総額：
$8.47M
収益：
-
当期純損益:
$-30.33M
株価収益率:
-0.0148
EPS:
-28.0369
ネットキャッシュフロー:
$-24.28M
1週間 パフォーマンス:
-13.32%
1か月 パフォーマンス:
-42.22%
6か月 パフォーマンス:
-84.23%
1年 パフォーマンス:
-96.51%
1日の値動き範囲:
$0.413
$0.4531
1週間の範囲:
$0.4107
$0.49
52週間の値動き範囲:
$0.1614
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Compare MBRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.4153 | 12.26M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
507.77 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.57 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
766.56 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.19 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
190.52 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
Form 8K Moleculin Biotech Inc For: 29 September By Investing.com - Investing.com Nigeria
Moleculin completes enrollment in Annamycin AML trial Part A - Investing.com
Moleculin Biotech completes Part A enrollment in MIRACLE; 89 patients, Q1 2027 readout on track - TradingView
A leukemia trial finished enrolling 89 people. Full results are expected in early 2027. - Stock Titan
Moleculin reports cardiac safety data for Annamycin in study By Investing.com - Investing.com Australia
Moleculin Biotech Reports Peer-Reviewed Cardiac Safety Analysis of Annamycin - kalkinemedia.com
Moleculin reports cardiac safety data for Annamycin in study - Investing.com
A review found no signs of heart damage in 90 patients given a cancer drug - Stock Titan
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com Nigeria
Moleculin presents preclinical pancreatic cancer data at AACR By Investing.com - Investing.com Australia
Moleculin presents preclinical pancreatic cancer data at AACR - Investing.com
Annamycin Turns 'Cold” Pancreatic Tumors 'Hot” in New Preclinical Data Presented at AACR - The Manila Times
Form 8-K Moleculin Biotech, Inc. For: Sep 25 - StreetInsider
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR - GlobeNewswire
Moleculin Biotech (NASDAQ: MBRX) Obtains Mexican Patent No. 436849 and Issues 888,400 Shares via ATM Offering - kalkinemedia.com
Moleculin Biotech Announces Mexican Patent Approval and ATM Share Offering Completion - Kalkine Media
Moleculin receives Mexican patent for Annamycin formulation By Investing.com - Investing.com Nigeria
Moleculin Biotech (MBRX) Strengthens IP with Mexican Patent Amid Challenging Valuation - GuruFocus
Moleculin Series I Warrant Exercise Price Cut to $0.51 After ATM Sales - Minichart
Form 8K Moleculin Biotech Inc For: 23 September By Investing.com - Investing.com Canada
Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio - TipRanks
Moleculin receives Mexican patent for Annamycin formulation - Investing.com
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 - GlobeNewswire
Moleculin Biotech stock falls 32.71 percent on September 21 - AD HOC NEWS
Form 8K Moleculin Biotech Inc For: 18 September - Investing.com India
Form 8K Moleculin Biotech Inc For: 18 September By Investing.com - Investing.com Nigeria
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation - Investing.com
Moleculin Biotech Faces Nasdaq Delisting Risk After Notice - TipRanks
Moleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Moleculin Showcases New Annamycin Data at September Conferences - TipRanks
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings - marketscreener.com
Moleculin to Showcase New Annamycin Data at AACR Conference - GlobeNewswire
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Australia
MBRX: Annamycin's phase III AML trial shows 3x higher remission rates and zero cardiotoxicity - TradingView
Moleculin Biotech at H.C. Wainwright conference: aml hope builds - Investing.com
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
A biotech’s clinical update goes online before New York investor meetings - Stock Titan
Moleculin Biotech (MBRX) Holds Above $0.77 as Biotech Sector Watches Key Resistance at $0.81Trend Following Picks - siam.in
MBRX Should I Buy - Intellectia AI
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech Inc. (MBRX) Peer Comparison – Compare with Others - Value Research
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - ACCESS Newswire
Moleculin Biotech Updates Investors with New Presentation - TipRanks
Moleculin (NASDAQ: MBRX) posts investor presentation online - Stock Titan
Moleculin Biotech Inc. (MBRX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MBRX Q2 2026 Earnings: Loss Narrows More Than Expected, but Shares Slip 5.6%Guidance Update - careplusvn.com
MOLECULIN BIOTECH, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $3 FROM $22 - webull.com
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.26%
0.58%
大文字化:
|
ボリューム (24 時間):